Mepolizumab attenuates ILC2s proliferation and activity in adults with severe eosinophilic asthma. Brusselle G, Riemann S, Maes T. Respirology 2023 May 10. doi: 10.1111/resp.14517.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Brusselle G, Riemann S, Maes T. Mepolizumab attenuates ILC2s proliferation and activity in adults with severe eosinophilic asthma. Respirology 2023 May 10. doi: 10.1111/resp.14517.
PMID: 37164907